insights_auto
Why is BNTX up ၅.၃၂%?
Dive Deeperchevron_right
BNTX:NASDAQ
BioNTech SE - ADR
၉၆.၉၆ US$
arrow_upward
+၅.၃၂%(+၄.၉၀) 1D
၉၆.၉၆ US$
၀.၀၀% (၀.၀၀)
bedtimeAfter hours
Closed: အောက် ၉, GMT-၄ ၁၆:၀၀:၀၁ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
၉၂.၄၅ US$
High
၉၇.၄၀ US$
Low
၉၂.၃၀ US$
Mkt. cap
ဋေ ၂.၄၄ ထ
Avg. vol.
၉.၉၄ သိန်း
Volume
၁.၃၂ သန်း
52-wk high
၁၂၃.၉၈ US$
52-wk low
၇၉.၅၂ US$
EPS
-၇.၅၂ US$
Beta
၁.၂၂
Shares outstanding
၂၅.၁၂ ကုဋေ
No. of employees
၈ ထောင်
Open
၉၂.၄၅ US$
High
၉၇.၄၀ US$
Low
၉၂.၃၀ US$
Mkt. cap
ဋေ ၂.၄၄ ထ
Avg. vol.
၉.၉၄ သိန်း
Volume
၁.၃၂ သန်း
52-wk high
၁၂၃.၉၈ US$
52-wk low
၇၉.၅၂ US$
EPS
-၇.၅၂ US$
Beta
၁.၂၂
Shares outstanding
၂၅.၁၂ ကုဋေ
No. of employees
၈ ထောင်
News stories
From web sources and news partners
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၁ ရက်
BioNTech's 5.4% Friday Rally Came Without a Company Catalyst — and the Insider Trades Kept Coming
Stock Titan
·
ပြီးခဲ့သည့် ၁ ရက်
Under a trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 36,209 and 27,000 shares.
Benzinga
·
ပြီးခဲ့သည့် ၂ ရက်
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
Yahoo Finance
·
ပြီးခဲ့သည့် ၂ ရက်
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR